These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24141556)

  • 1. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
    Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
    Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
    Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
    In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
    Komurcuoglu B; Cirak AK; Kirakli SC; Polat G; Yucel N; Usluer O; Erer O; Balci G; Gayaf M; Guldaval F; Aktogu S; Guclu S; Ozsoz A; Halilcolar H
    Tumori; 2014; 100(1):55-9. PubMed ID: 24675492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
    Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
    J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
    Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
    Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
    Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
    Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M
    Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in malignant pleural mesothelioma: a retrospective study.
    Suzuki H; Hirashima T; Kobayashi M; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Okafuji K; Shiroyama T; Morimura O; Morita S; Kawase I
    Intern Med; 2012; 51(7):707-10. PubMed ID: 22466824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.
    Chirieac LR; Barletta JA; Yeap BY; Richards WG; Tilleman T; Bueno R; Baldini EH; Godleski J; Sugarbaker DJ
    J Clin Oncol; 2013 Dec; 31(36):4544-9. PubMed ID: 24248693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
    Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
    Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
    Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
    Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
    Proto C; Signorelli D; Mallone S; Prelaj A; Lo Russo G; Imbimbo M; Galli G; Ferrara R; Ganzinelli M; Leuzzi G; Greco FG; Calareso G; Botta L; Gatta G; Garassino M; Trama A
    Clin Lung Cancer; 2019 Nov; 20(6):e652-e660. PubMed ID: 31377142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
    Nojiri S; Gemba K; Aoe K; Kato K; Yamaguchi T; Sato T; Kubota K; Kishimoto T
    Jpn J Clin Oncol; 2011 Jan; 41(1):32-9. PubMed ID: 20798232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
    Baud M; Strano S; Dechartres A; Jouni R; Triponez F; Chouaid C; Forgez P; Damotte D; Roche N; Régnard JF; Alifano M
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1305-11. PubMed ID: 23072703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.